Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elevated levels of C-reactive protein (CRP) are associated with increased risks of ischemic heart disease and ischemic cerebrovascular disease. We tested whether this is a causal association. METHODS: We studied 10,276 persons from a general population cohort, including 1786 in whom ischemic heart disease developed and 741 in whom ischemic cerebrovascular disease developed. We examined another 31,992 persons from a cross-sectional general population study, of whom 2521 had ischemic heart disease and 1483 had ischemic cerebrovascular disease. Finally, we compared 2238 patients with ischemic heart disease with 4474 control subjects and 612 patients with ischemic cerebrovascular disease with 1224 control subjects. We measured levels of high-sensitivity CRP and conducted genotyping for four CRP polymorphisms and two apolipoprotein E polymorphisms. RESULTS: The risk of ischemic heart disease and ischemic cerebrovascular disease was increased by a factor of 1.6 and 1.3, respectively, in persons who had CRP levels above 3 mg per liter, as compared with persons who had CRP levels below 1 mg per liter. Genotype combinations of the four CRP polymorphisms were associated with an increase in CRP levels of up to 64%, resulting in a theoretically predicted increased risk of up to 32% for ischemic heart disease and up to 25% for ischemic cerebrovascular disease. However, these genotype combinations were not associated with an increased risk of ischemic vascular disease. In contrast, apolipoprotein E genotypes were associated with both elevated cholesterol levels and an increased risk of ischemic heart disease. CONCLUSIONS: Polymorphisms in the CRP gene are associated with marked increases in CRP levels and thus with a theoretically predicted increase in the risk of ischemic vascular disease. However, these polymorphisms are not in themselves associated with an increased risk of ischemic vascular disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional biomarkers, including apo B, lipoprotein(a), high-sensitivity C-reactive protein (CRP), coronary artery calcification score, and ankle-brachial index, are independent risk factors associated with increased risk of ASCVD events and may be helpful when the lipid management goal is unclear.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [284]
In the citing paper
“The value of hsCRP as a CV risk factor appears similar to that of conventional CV risk factors – hsCRP is not a causal factor for CV disease and serves as a biomarker only [36].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [36]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“Yet, despite the high CV morbidity and mortality risk, PAD patients are usually inadequately managed compared with CAD patients [511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationFasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Mendelian randomization: prospects, potentials, and limitations
Smith, G. D. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh132 · Cited by 1,222
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877
Cited by
Items 201–300 of 840
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.010 · Cited by 72
Self-citationAn ELISA Assay for Quantifying Monomeric C-Reactive Protein in Plasma
Zhang, L., Li, H., Li, W., Shen, Z.-Y., Wang, Y.-D., Ji, S., & Wu, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00511 · Cited by 75
Association of inflammation with worsening HOMA-insulin resistance
Park, K., Steffes, M., Lee, D.-H., Himes, J. H., & Jacobs, D. R. (2009) · Diabetologia · doi:10.1007/s00125-009-1486-5 · Cited by 72
C-Reactive Protein and Coronary Heart Disease: All Said—Is Not It?
Strang, F., & Schunkert, H. (2014) · Mediators of Inflammation · doi:10.1155/2014/757123 · Cited by 81
Anti-depressant medication use and C-reactive protein: Results from two population-based studies
Hamer, M., Batty, G., Marmot, M. G., Singh-Manoux, A., & Kivimäki, M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.09.013 · Cited by 71
Xie, S., Galimberti, F., Olmastroni, E., Lüscher, T. F., Carugo, S., Catapano, A. L., Casula, M., META-LIPID Group, Catapano, A. L., Casula, M., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae034 · Cited by 74
C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target?
Hingorani, A. D., Shah, T., Casas, J. P., Humphries, S. E., & Talmud, P. J. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.115923 · Cited by 70
Payne, R. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04219.x · Cited by 91
CHRNA3genotype, nicotine dependence, lung function and disease in the general population
Kaur‐Knudsen, D., Nordestgaard, B. G., & Bojesen, S. E. (2012) · European Respiratory Journal · doi:10.1183/09031936.00176811 · Cited by 70
Self-citationInflammation Markers and Metabolic Characteristics of Subjects With 1-h Plasma Glucose Levels
Bardini, G., Dicembrini, I., Cresci, B., & Rotella, C. M. (2009) · Diabetes Care · doi:10.2337/dc09-1342 · Cited by 70
Kim, S. J., Moon, G. J., & Bang, O. Y. (2013) · Journal of Stroke · doi:10.5853/jos.2013.15.1.27 · Cited by 78
Elevated neutrophil to lymphocyte ratio and ischemic stroke risk in generally healthy adults
Suh, B., Shin, D. W., Kwon, H., Yun, J. M., Yang, H. K., Ahn, E., Lee, H., Park, J., & Cho, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183706 · Cited by 68
Aalto, K., Maksimow, M., Juonala, M., Viikari, J. S. A., Jula, A., Kähönen, M. A. P., Jalkanen, S., Raitakari, O. T., & Salmi, M. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.238030 · Cited by 66
Interactions among gender, age, hypertension and C‐reactive protein in coronary vasospasm
Hung, M., Hsu, K., Hung, M., Cheng, C., & Cherng, W. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02360.x · Cited by 66
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker, P. M. (2013) · Europe PMC (PubMed Central) · Cited by 86
Linking inflammation and thrombosis: Role of C-reactive protein
Fay, W. P. (2010) · World Journal of Cardiology · doi:10.4330/wjc.v2.i11.365 · Cited by 64
Molecular genetics of atherosclerosis
Roy, H., Bhardwaj, S., & Ylä‐Herttuala, S. (2009) · Human Genetics · doi:10.1007/s00439-009-0654-5 · Cited by 72
“increase in the risk of ischemic vascular disease (Hingorani et al. 2009; Zacho et al. 2008).”
BackgroundNordestgaard, B. G., & Tybjærg-Hansen, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834477d2 · Cited by 67
Self-citationNew and Emerging Risk Factors for Coronary Heart Disease
Akhabue, E., Thiboutot, J. P., Cheng, J.-W., Lerakis, S., Vittorio, T. J., Christodoulidis, G., Grady, K. M., & Kosmas, C. E. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31828aab45 · Cited by 72
Plasma YKL-40 and Total and Disease-Specific Mortality in the General Population
Johansen, J. S., Bojesen, S. E., Tybjærg‐Hansen, A., Mylin, A. K., Price, P. A., & Nordestgaard, B. G. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.146530 · Cited by 62
Self-citationCardiovascular risk in patients with rheumatoid arthritis
Lauper, K., & Gabay, C. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0632-2 · Cited by 71
Genetic Loci Associated with C-Reactive Protein Levels and Risk Of Coronary Heart Disease
Smith, J. G., & Newton‐Cheh, C. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0099-3 · Cited by 61
Deepak, D. S., Daousi, C., Javadpour, M., Clark, D. J., PERRY, Y. S., Pinkney, J. H., & MacFarlane, I. A. (2010) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2010.02.002 · Cited by 62
Cheng, J. M., Oemrawsingh, R. M., García‐García, H. M., Akkerhuis, K. M., Kardys, I., de Boer, S. P. M., Langstraat, J. S., Regar, E. S., van Geuns, R., Serruys, P. W. J. C., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.08.013 · Cited by 64
Rasmussen, K. L., Nordestgaard, B. G., & Nielsen, S. F. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.287581 · Cited by 62
Self-citationKjaergaard, A. D., Johansen, J. S., Bojesen, S. E., & Nordestgaard, B. G. (2015) · Stroke · doi:10.1161/strokeaha.114.007657 · Cited by 64
Self-citationPossible mechanisms of C-reactive protein mediated acute myocardial infarction
Asare, P. F., Wang, Y., Shi, Y., Agyemang, K., Akinyi, M., Zhang, Q., & Fan, G. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.04.010 · Cited by 64
Yang, X., Hu, W., Zhang, Q., Wang, Y., & Sun, L. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00548.x · Cited by 60
van Durme, Y. M. T. A., Verhamme, K. M. C., Aarnoudse, A. L. H. J., Pottelberge, G. R. V., Hofman, A., Witteman, J. C. M., Joos, G., Brusselle, G., & Stricker, B. H. C. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200810-1540oc · Cited by 65
Wium-Andersen, M. K., Ørsted, D. D., & Nordestgaard, B. G. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.150870 · Cited by 61
Self-citationBarbati, E., Specchia, C., Villella, M., Rossi, M. L., Barlera, S., Bottazzi, B., Crociati, L., d’Arienzo, C., Fanelli, R., Garlanda, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053030 · Cited by 63
Kaur-Knudsen, D., Bojesen, S. E., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.9870 · Cited by 58
Self-citationAmano, K., Maeda, I., Morita, T., Miura, T., Inoue, S., Ikenaga, M., Matsumoto, Y., Baba, M., Sekine, R., Yamaguchi, T., et al. (2016) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2015.11.025 · Cited by 58
F ifty Y ears of R esearch in ARDS. Genomic Contributions and Opportunities
Reilly, J. P., Christie, J. D., & Meyer, N. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201702-0405cp · Cited by 64
Gedebjerg, A., Bjerre, M., Kjaergaard, A. D., Nielsen, J. S., Rungby, J., Brandslund, I., Mæng, M., Beck‐Nielsen, H., Vaag, A. A., Sørensen, H. T., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1353 · Cited by 67
Kobylecki, C. J., Afzal, S., Smith, G. D., & Nordestgaard, B. G. (2015) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.104497 · Cited by 62
Self-citationZacho, J., Yazdanyar, S., Bojesen, S. E., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2010) · International Journal of Cancer · doi:10.1002/ijc.25375 · Cited by 57
Self-citationRamel, A., Martínez, J. A., Kiely, M. E., Bandarra, N. M., & Þórsdóttir, I. (2010) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2010.99 · Cited by 62
Overcoming Challenges With Statin Therapy
Spence, J. D., & Dresser, G. K. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002497 · Cited by 56
Rasmussen, K. L., Nordestgaard, B. G., Frikke‐Schmidt, R., & Nielsen, S. F. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.223 · Cited by 53
“The epidemiological findings were substantiated byMendelian randomization where plasma complement C3 determining genotypes, combined into a weighted or a simple gene score, were used to predict risk of AD based on the epidemiological associations, and subsequently, compared with the observational risk of AD, as done p…”
MethodSelf-citationC-Reactive Protein and Coronary Disease: Is There a Causal Link?
Danesh, J. N., & Pepys, M. B. (2009) · Circulation · doi:10.1161/circulationaha.109.907212 · Cited by 61
Translational Studies of Lipoprotein-Associated Phospholipase A2 in Inflammation and Atherosclerosis
Ferguson, J. F., Hinkle, C. C., Mehta, N. N., Bagheri, R., DerOhannessian, S. L., Shah, R., Mucksavage, M. I., Bradfield, J. P., Hakonarson, H. H., Wang, X., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.019 · Cited by 60
Cohort Profile Update: The Danish HIV Cohort Study (DHCS)
Omland, L. H., Ahlström, M. G., & Obel, N. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu153 · Cited by 53
Hegazy, S. H., Thomassen, J. Q., Rasmussen, I. J., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12568 · Cited by 58
Self-citationC-Reactive Protein Is a Determinant of First-Ever Stroke: Prospective Nested Case-Referent Study
Andersson, J. S. O., Johansson, L., Ladenvall, P., Wiklund, P.-G., Stegmayr, B., Jern, C., & Boman, K. (2009) · Cerebrovascular Diseases · doi:10.1159/000214217 · Cited by 58
Genetic Markers of Inflammation and Their Role in Cardiovascular Disease
Raman, K., Chong, M., Akhtar-Danesh, G.-G., D’Mello, M. J. J., Hasso, R., Ross, S. A., Xu, F., & Paré, G. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.06.025 · Cited by 67
Stender, S., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjaerg-Hansen, A. (2011) · Hepatology · doi:10.1002/hep.24046 · Cited by 56
Self-citationvan Wijk, D. F., Boekholdt, S. M., Wareham, N. J., Ahmadi‐Abhari, S., Kastelein, J. J. P., Stroes, E. S. G., & Khaw, K. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301736 · Cited by 60
Markers of Inflammation and Risk of Coronary Heart Disease
Sarwar, N., Thompson, A. J., & Di Angelantonio, E. (2009) · Disease Markers · doi:10.1155/2009/851962 · Cited by 43
Extreme Bilirubin Levels as a Causal Risk Factor for Symptomatic Gallstone Disease
Stender, S., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6465 · Cited by 53
Self-citationWennberg, P., Wensley, F., Angelantonio, E. D., Johansson, L., Boman, K., Rumley, A., Lowe, G. D. O., Hallmans, G., Danesh, J., & Jansson, J. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.05.015 · Cited by 53
Langsted, A., Varbo, A., Kamstrup, P. R., & Nordestgaard, B. G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1096 · Cited by 53
Self-citationLi, H., Wang, J., Wu, Y., Zhang, L., Liu, Z.-P., Filep, J. G., Potempa, L. A., Wu, Y., & Ji, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.555318 · Cited by 52
Gruppen, E. G., Kunutsor, S. K., Kieneker, L. M., van der Vegt, B., Connelly, M. A., de Bock, G. H., Gansevoort, R. T., Bakker, S. J. L., & Dullaart, R. P. F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12953 · Cited by 56
Mehta, N. N., Matthews, G. J., Krishnamoorthy, P. M., Shah, R. D., McLaughlin, C., Patel, P., Budoff, M. J., Chen, J., Wolman, M. A., Go, A. S., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht481 · Cited by 51
Çolak, Y., Afzal, S., Lange, P., & Nordestgaard, B. G. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty077 · Cited by 51
Self-citationYao, H., Shi, P., Zhang, L., Fan, X., Shao, Q., & Cheng, Y. (2010) · Molecular BioSystems · doi:10.1039/b925612a · Cited by 50
Human Validation of Genes Associated With a Murine Atherosclerotic Phenotype
Pasterkamp, G., van der Laan, S. W., Haitjema, S., Asl, H. F., Siemelink, M. A., Bezemer, T., van Setten, J., Dichgans, M., Malik, R., Worrall, B. B., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306958 · Cited by 50
The interleukin-6 pathway and atherosclerosis
Boekholdt, S. M., & Stroes, E. S. G. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60361-4 · Cited by 61
Molli, A. E. I., Steinhardt, A. P., López, A. P., González, C. D., Vilarino, J. F., Frechtel, G. D., & Cerrone, G. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0190528 · Cited by 52
Karakas, M., & Köenig, W. (2009) · Herz · doi:10.1007/s00059-009-3305-7 · Cited by 56
“Mendelian randomization in four independent cross-sectional studies and prospective cohorts has demonstrated, that elevated CRP associates with an increased risk of cardiovascular disease (CVD), that genetic variation in the CRP gene associates with increased CRP levels, but that this genetic variation in the CRP gene…”
BackgroundXu, G., Zhou, Z., Zhu, W., Fan, X., & Liu, X. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.04.018 · Cited by 49
Iso, H., Noda, H., Ikeda, A., Yamagishi, K., Inoue, M., Iwasaki, M., & Tsugane, S. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11999 · Cited by 48
Nordestgaard, B. G. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283307bfe · Cited by 48
Self-citationBody Mass and White Matter Integrity: The Influence of Vascular and Inflammatory Markers
Bettcher, B. M., Walsh, C. M., Watson, C., Miller, J. W., Green, R., Patel, N., Miller, B. L., Neuhaus, J. M., Yaffe, K. S., & Kramer, J. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077741 · Cited by 55
Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.038 · Cited by 47
Self-citationAbd, T. T., Eapen, D. J., Bajpai, A., Goyal, A., Dollar, A. L., & Sperling, L. S. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0164-5 · Cited by 52
Provan, S. A., Angel, K., Semb, A. G., Mowinckel, P., Agewall, S., Atar, D., & Kvien, T. K. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.100689 · Cited by 53
Mendelian Randomization: Principles and its usage in Lp(a) research
Lamina, C. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.013 · Cited by 52
Flood, D. G., Marek, G. J., & Williams, M. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.021 · Cited by 49
Ørsted, D. D., Nordestgaard, B. G., Jensen, G. B., Schnohr, P., & Bojesen, S. E. (2011) · European Urology · doi:10.1016/j.eururo.2011.11.007 · Cited by 46
Self-citationAssociation of exome sequences with plasma C-reactive protein levels in >9000 participants
Schick, U. M., Auer, P. L., Bis, J. C., Lin, H., Wei, P., Pankratz, N., Lange, L. A., Brody, J., Stitziel, N. O., Kim, D. S., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu450 · Cited by 44
Zhuang, Q., Shen, C., Chen, Y., Zhao, X., Wei, P., Sun, J., Ji, Y., Chen, X., & Yang, S. (2019) · BMC Medical Genetics · doi:10.1186/s12881-019-0910-z · Cited by 54
de la Monte, S. M., Chen, G., Rivera, E. J., & Wands, J. R. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3305-3 · Cited by 52
Qasim, A. N., Budharaju, V., Mehta, N. N., St Clair, C., Farouk, S., Braunstein, S., Schutta, M., Iqbal, N., Rader, D. J., & Reilly, M. P. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03879.x · Cited by 43
Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein?
Zimmermann, O., Bienek‐Ziolkowski, M., Wolf, B., Vetter, M., Baur, R., Mailänder, V., Hombach, V., & Torzewski, J. (2009) · Basic Research in Cardiology · doi:10.1007/s00395-009-0026-2 · Cited by 47
“In vitro studies have been supplemented by in vivo investigations with contradictory results [16, 23, 40].”
ResultOmland, T., & White, H. D. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255190 · Cited by 48
Tabák, Á. G., Kivimäki, M., Brunner, E. J., Lowe, G. D. O., Jokela, M. M., Akbaraly, T. N., Singh‐Manoux, A., Ferrie, J. E., & Witte, D. R. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0277 · Cited by 53
C-Reactive Protein-Mediated Vascular Injury Requires Complement
Hage, F. G., Oparil, S., Xing, D., Chen, Y.-F., McCrory, M. A., & Szalai, A. J. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.205377 · Cited by 43
Copy Number Variation in Glutathione S-Transferases M1 and T1 and Ischemic Vascular Disease
Nørskov, M. S., Frikke‐Schmidt, R., Loft, S. H., Sillesen, H. H., Grande, P., Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.959809 · Cited by 43
Self-citationLipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 47
“While there is no doubt that statins can improve systemic inflammation (reduction of hsCRP), whether this action is related to their lipid lowering properties is still a matter of discussion (43, 44, 80).”
BackgroundRidker, P. M. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12862 · Cited by 49
Saeedi, R., Johns, K., Frohlich, J. J., Bennett, M. T., & Bondy, G. P. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0054-x · Cited by 42
Depression, Coronary Artery Disease, and Physical Activity: How Much Exercise Is Enough?
Peterson, J. C., Charlson, M. E., Wells, M. T., & Altemus, M. M. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.10.003 · Cited by 52
Rode, L., Bojesen, S. E., Weischer, M., & Nordestgaard, B. G. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu119 · Cited by 40
Self-citationC reactive protein and alpha1-antitrypsin: relationship between levels and gene variants
Ottaviani, S., Gorrini, M., Scabini, R., Kadija, Z., Paracchini, E., Mariani, F., Ferrarotti, I., & Luisetti, M. (2011) · Translational research · doi:10.1016/j.trsl.2010.12.014 · Cited by 42
Löffler, S., Löffler-Ensgraber, M., Fehsel, K., & Klimke, A. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833643fd · Cited by 46
Assa, S., Hummel, Y. M., Voors, A. A., Kuipers, J., Westerhuis, R., Groen, H., Bakker, S. J. L., Kobold, A. C. M., van Oeveren, W., Struck, J., et al. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.11.010 · Cited by 44
Williams, K. J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320065 · Cited by 47
Chaudhuri, J. R., Kandadai, R. M., Umamahesh, M., Alluri, S., Balaraju, B., & Bandaru, V. C. S. S. (2013) · PubMed Central · Cited by 61
Emerging Genomic Applications in Coronary Artery Disease
Damani, S. B., & Topol, E. J. (2011) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.12.016 · Cited by 43
Akinkugbe, A. A., Avery, C. L., Barritt, A. S., Cole, S. R., Lerch, M. M., Mayerle, J. V., Offenbacher, S., Petersmann, A., Nauck, M. A., Völzke, H., et al. (2017) · Journal of Dental Research · doi:10.1177/0022034517720924 · Cited by 45
Ferreira, J. P., Vasques‐Nóvoa, F., Neves, J. S., Zannad, F. M., & Leite-Moreira, A. F. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117461 · Cited by 43
Interleukin-6 “Trans-Signaling” and Ischemic Vascular Disease: The Important Role of Soluble gp130
Morieri, M. L., Passaro, A., & Zuliani, G. (2017) · Mediators of Inflammation · doi:10.1155/2017/1396398 · Cited by 37
“Large genetic human studies, using Mendelian randomization approaches, have clearly showed that IL-6 pathway is causally involved in the onset ofmyocardial infarction.”
BackgroundOemrawsingh, R. M., Cheng, J. M., Akkerhuis, K. M., Kardys, I., Deǧertekin, M., van Geuns, R., Daemen, J., Boersma, E. H., Serruys, P. W. J. C., & van Domburg, R. T. (2016) · EuroIntervention · doi:10.4244/eijy15m07_04 · Cited by 44
The relevance of the association between inflammation and atrial fibrillation
Alegret, J. M., Aragonès, G., Elosúa, R., Beltrán‐Debón, R., Hernández‐Aguilera, A., Romero‐Menor, C., Camps, J., & Joven, J. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12047 · Cited by 49
The influence of low-grade inflammation on platelets in patients with stable coronary artery disease
Larsen, S. B., Grove, E. L., Würtz, M., Neergaard‐Petersen, S., Hvas, A., & Kristensen, S. D. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1007 · Cited by 45
New evidence on the role of inflammation in CVD risk
Lorenzatti, A. J., & Servato, L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000625 · Cited by 42
C-Reactive Protein in Human Atherogenesis: Facts and Fiction
Zimmermann, O., Li, K., Zaczkiewicz, M., Graf, M., Liu, Z., & Torzewski, J. (2014) · Mediators of Inflammation · doi:10.1155/2014/561428 · Cited by 43
Oei, L., Campos‐Obando, N., Dehghan, A., Oei, E. H. G., Stolk, L., van Meurs, J. B. J., Hofman, A., Uitterlinden, A. G., Franco, O. H., Zillikens, M. C., et al. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2578-0 · Cited by 40
“examining the relationship between polymorphisms in the CRP gene and ischemic vascular disease [17].”
Background
Metadata
- Authors
- Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Rigshospitalet (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-30
- Volume
- 359
- Issue
- 18
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081615427
- Cited by
- 839
- References
- 36
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 21 · 2023: 21 · 2022: 26 · 2021: 25 · 2020: 33 · 2019: 25 · 2018: 28 · 2017: 40 · 2016: 48 · 2015: 44 · 2014: 61 · 2013: 56 · 2012: 76
- FWCI
- 102.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Keywords
- C-reactive protein, ischemic heart disease, ischemic cerebrovascular disease, ischemic vascular disease, CRP gene polymorphisms, apolipoprotein E, high-sensitivity CRP, genetic association, cholesterol levels, causal relationship
- MeSH terms
- C-Reactive Protein, Cerebrovascular Disorders, Cross-Sectional Studies, Female, Humans, Male, Polymorphism, Genetic, Risk Factors, Cohort Studies, Biomarkers, Myocardial Ischemia, Genetic Predisposition to Disease, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.